JAZZ vs. WAT: Jazz Pharmaceuticals vs. Waters Stock Comparison
How do Jazz Pharmaceuticals (JAZZ) and Waters (WAT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Jazz Pharmaceuticals (JAZZ) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while WAT is classified in Life Sciences Tools & Services.
| Profile Item | JAZZ | WAT |
|---|---|---|
| Name | Jazz Pharmaceuticals plc | Waters Corporation |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| GICS Sub-Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 15.07 billion USD | 44.93 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2007 | November 17, 1995 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| Total Return (1Y) | 84.44% | 27.70% |
| Total Return (3Y, Annualized) | 27.57% | 23.32% |
| Total Return (5Y, Annualized) | 12.88% | 6.27% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| Volatility (1Y, Annualized) | 38.74% | 35.45% |
| Beta (5Y) | 0.33 | 1.13 |
| Max Drawdown (5Y) | -42.03% | -36.47% |
| Avg. Volume (3M) | 878.80K | 816.72K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 0.66 |
| Sortino Ratio (1Y) | 4.14 | 0.98 |
Profitability
ROE (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 5.05% and Waters (WAT) at 1.12% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12%
- Max
- 109.18%
- Q3
- 6.23%
- WAT
- 1.12%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 4.37% and Waters (WAT) at 1.76% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.76%
- Max
- 18.05%
- Q3
- 4.78%
- WAT
- 1.76%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Jazz Pharmaceuticals (JAZZ) at 30.17% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.38%
- Max
- 83.12%
- Q3
- 14.77%
- WAT
- 11.38%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| ROE (TTM) | 5.05% | 1.12% |
| ROA (TTM) | 6.92% | 2.36% |
| Net Margin (TTM) | 4.37% | 1.76% |
| Operating Margin (TTM) | 30.17% | 11.38% |
| Gross Margin (TTM) | 91.10% | 49.83% |
Growth
Revenue Growth
Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Waters (WAT) at 6.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Waters (WAT) at 0.47% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| Revenue Growth (YoY) | 4.88% | 6.99% |
| Revenue Growth (3Y CAGR) | 5.26% | 2.12% |
| EPS Growth (YoY) | -167.51% | 0.47% |
| EPS Growth (3Y CAGR) | -- | -2.84% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Jazz Pharmaceuticals (JAZZ) shows current ratio of 1.82 against its industry benchmark, while Waters (WAT) has no reading this period.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- WAT
- --
Debt / Equity (MRQ)
Waters (WAT) at 0.34 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.34
- Max
- 1.42
- Q3
- 0.65
- WAT
- 0.34
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | -- |
| Debt / Equity (MRQ) | 1.35 | 0.34 |
| Net Debt / EBITDA | 1.39 | 3.23 |
Dividends
Dividend Yield (TTM)
Neither Jazz Pharmaceuticals (JAZZ) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- WAT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Jazz Pharmaceuticals (JAZZ) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- WAT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both look expensive on trailing earnings: Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer P/E ratio quartile, and Waters (WAT) at 191.46 is richer still, above its industry range.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
191.46
- WAT
- 191.46
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Waters (WAT) at 8.01 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.01
- Max
- 58.18
- Q3
- 25.77
- WAT
- 8.01
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and Waters (WAT) at 2.94 are valued close to their industries’ norm against book — neither stands out from peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- WAT
- 2.94
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | JAZZ | WAT |
|---|---|---|
| P/E Ratio (TTM) | 69.46 | 191.46 |
| P/S Ratio (TTM) | 3.19 | 8.01 |
| P/B Ratio (MRQ) | 3.59 | 2.94 |
| Free Cash Flow Yield (TTM) | 11.16% | -- |